Literature DB >> 9443615

Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel.

E S Woo1, A Monks, S C Watkins, A S Wang, J S Lazo.   

Abstract

UNLABELLED: Metallothioneins (MTs) are major thiol-containing intracellular proteins that bind metals, are induced by stress, and have been implicated in resistance to drugs and heavy metals.
PURPOSE: To examine the hypothesis that the protective functionality of MT may be dictated by its subcellular localization.
METHODS: We analyzed the basal MT content in 53 adherent cell lines of the National Cancer Institute (NCI) tumor panel and quantified the nuclear/cytoplasmic distribution of MT using confocal laser scanning microscopy and a recently described immunofluorescence-based algorithm.
RESULTS: Among these cell types we found a 400-fold range in the basal MT levels and a tenfold range in the ratio of the nuclear to cytoplasmic MT immunostaining that was independent of basal MT content. Total MT levels and nuclear/cytoplasmic distribution were independent of total glutathione content, suggesting autonomous regulation of these protective protein and nonprotein thiol pools. Approximately 50% (29/53) of the cell lines had a greater nuclear than cytoplasmic MT density and were defined as having a karyophilic phenotype. Tissue specificity of MT localization was seen with breast cancer cell lines, which were cytoplasmophilic, whereas prostate-derived cells were karyophilic. Among the 25000 unrestricted compounds in the NCI database, we detected a correlation between total basal MT levels and resistance to CdCl2, four Pt- and two Cu-containing compounds. High nuclear/cytoplasmic MT values correlated with resistance to six Cu-, six Pb-, and one Zn-containing compounds.
CONCLUSIONS: These results demonstrated significant diversity in MT content and subcellular localization in human tumor cells. Moreover, both basal MT levels and subcellular distribution appeared to be determinants of cellular responsiveness to metal-containing compounds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9443615     DOI: 10.1007/s002800050708

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  A multivariate insight into the in vitro antitumour screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets.

Authors:  G Musumarra; D F Condorelli; A S Costa; M Fichera
Journal:  J Comput Aided Mol Des       Date:  2001-03       Impact factor: 3.686

2.  Cellular zinc and redox buffering capacity of metallothionein/thionein in health and disease.

Authors:  Wolfgang Maret; Artur Krezel
Journal:  Mol Med       Date:  2007 Jul-Aug       Impact factor: 6.354

3.  Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.

Authors:  S L El Sharkawy; N F Abbas; M A Badawi; M A El Shaer
Journal:  J Clin Pathol       Date:  2006-03-30       Impact factor: 3.411

4.  A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology.

Authors:  P J Bugelski; U Atif; S Molton; I Toeg; P G Lord; D G Morgan
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

5.  The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenase.

Authors:  L J Jiang; W Maret; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

6.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

7.  Reaction of human metallothionein-3 with cisplatin and transplatin.

Authors:  Andrei V Karotki; Milan Vasák
Journal:  J Biol Inorg Chem       Date:  2009-06-18       Impact factor: 3.358

8.  Impact of overexpression of metallothionein-1 on cell cycle progression and zinc toxicity.

Authors:  Paul J Smith; Marie Wiltshire; Emeline Furon; John H Beattie; Rachel J Errington
Journal:  Am J Physiol Cell Physiol       Date:  2008-09-24       Impact factor: 4.249

Review 9.  Zinc and cancer: implications for LIV-1 in breast cancer.

Authors:  Bruce J Grattan; Hedley C Freake
Journal:  Nutrients       Date:  2012-07-04       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.